Linker Payload Services -Abzena

Linker Payload

We are experts at selecting the optimal payload-linker construct. Discover our bioconjugate & ADC payload-linker services.

Linker Payload Info Sheet Contact Us

Maximize your bioconjugate candidate with unmatched precision

>3000 linker-payloads developed that enhance the therapeutic efficacy & safety of bioconjugates.

>17 drug-linked & small molecule process development programs completed & transferred to GMP.

State-of-the-art preclinical through commercial ADC manufacturing capabilities at Bristol, PA.

Contact Us

Linker payload architecture is fundamental to the successful design of your drug candidate. Developing a safe and effective ADC drug requires the assembly of the desirable linker with the payload and the monoclonal antibody (mAb). Our extensive knowledge regarding mAbs, linkers, and payloads ensures a robust lead drug candidate.

Contact Us

A well designed linker helps the antibody to selectively deliver and release the drug to the tumor site. Our tailored solutions identify and de-risk your clinical candidates for development ensuring stage-specific milestones are met. By applying our expertise in highly potent small molecule process development, we utilize a Design of Experiment (DOE) based approach. Our capabilities include:

  • 100ml to 100L jacketed glass reactors allowing for efficient scale-up and ability to develop accurate scale-down models
  • Non-chromatographic purification methods such as precipitation and crystallization
  • Teledyne-Isco Torrent medium pressure chromatography systems capable of both normal and reversed phase purification up to 3.8kg columns
  • Novasep Hipersep high pressure chromatography skids capable of batch purification of more than 1kg of material in a single processing day

Leverage our advanced linker payload solutions.

We are dedicated to advancing the frontiers of medicine through our specialized linker payload solutions for bioconjugates and ADCs. Our comprehensive suite of services encompasses everything from precise payload design to GMP manufacturing, backed by a deep understanding of monoclonal antibodies and innovative linker technologies.

Linker Payload Services

To accelerate lead drug candidate selection, we apply our knowledge in linker payload design and synthesis, high potency materials, and analytical method development to develop your complex ADCs.

Linker Payload Design & Synthesis

Supporting your candidate ranking and lead selection process, we determine the optimal design of linker payload architecture and profiling in a series of in silico, ...

Learn More

Analytical Method Development & Validation

Your product development program will be accelerated by leveraging our extensive in-house capabilities, technologies, and knowledge to deliver methods tailored to your molecule of interest.

Learn More

Highly Potent Materials

Utilizing a combination of technology, infrastructure, and expertise, we provide you with seamless, flexible highly potent API development and manufacturing tailored to your specific needs.

Learn More

Tailored processes, reliably delivered

Linker-payload processes are developed and transferred directly to our cGMP manufacturing team minimizing challenges seen during process transfers. We develop the most effective processes for manufacturing at toxicology, clinical, and commercial scale using quality by design (QbD) principles.

Our expert knowledge of cGMP manufacturing enables us to successfully transfer existing processes into our facilities or develop a new innovative process, when needed, to meet your program needs. Processes follow ICH Product Lifecycle guidelines which ensure a robust and well characterized scalable manufacturing process.

Utilizing robust analytics, we ensure the right product quality attributes for your program.

Contact Us

Preclinical Analytical Development Support

Bioconjugate & ADC Formulation Development - Abzena

Abzena provides a robust suite of analytical method development services designed to support linker payload design and synthesis. Analytical methods verify the linker’s identity, monitor payload stability, and ensure optimal process conditions during ADC conjugation steps. Our advanced characterization capabilities help confirm the final product and detect potentially harmful impurities or byproducts.

Analytical Method Development
“We required a partner who not only shared our commitment to innovation but also possessed the deep technical expertise necessary to guide us through the complexities of ADC development. Abzena has been that partner for us. From the initial stages of linker payload design to the final steps of regulatory submission, their team has demonstrated exceptional proficiency and dedication. Working with Abzena, we have been impressed by their ability to integrate sophisticated design with rigorous analytical validation, all while maintaining a clear focus on regulatory compliance. Their proactive communication and adaptability have been particularly invaluable, ensuring that our projects not only meet but exceed the rigorous standards required in our field.”

Recent Customer

Linker Payload FAQs

What makes linker-payload design so critical in ADC and bioconjugate development?

Linker-payload design determines ADC stability, tumor‑specific release, therapeutic index, and safety—enabling stable circulation and precise payload release only at the disease site.

How does Abzena ensure precision in engineering linker‑payload constructs?

Abzena applies precision engineering, designing linkers tuned for stability, release kinetics, and conjugation compatibility, ensuring optimal performance of ADCs and other bioconjugates.

What advanced linker technologies does Abzena offer?

A key platform is ThioBridge® technology, which enables robust, stable, and site‑specific re‑bridging of disulfides, improving ADC homogeneity and therapeutic performance.

What types of payloads can Abzena support in ADC development?

Abzena works with a wide array of cytotoxic payloads—from traditional chemotherapeutics to advanced high‑potency molecules—selected and tailored for maximal therapeutic effect.

How does Abzena guide candidate selection and developability for ADC programs?

Abzena provide candidate ranking, in silico modeling, in vitro testing, ex vivo studies, and matrix evaluation frameworks to de‑risk development and ensure scalability from the outset.

What capabilities does Abzena have for handling highly potent materials?

Abzena supports both small‑scale (gram) and large‑scale (kilogram) production under strict OEL controls (down to 1 ng/m³), supported by engineering controls and cGMP suites.

How does Abzena support the scale‑up and manufacturing of ADC linker‑payloads?

With cGMP‑compliant facilities, 100 mL–100 L reactor systems, non‑chromatographic purification, and advanced chromatography tools, Abzena ensures efficient scale‑up and manufacturability.

How extensive is Abzena’s experience in designing and synthesizing complex linker‑payloads?

Abzena brings over 20 years of experience, thousands of synthesized linker‑payload variants, and strong SAR development across payload classes such as auristatins, maytansinoids, PBD dimers, and custom molecules.

What analytical methods ensure the quality and compliance of Abzena’s linker‑payloads?

Abzena conducts phase‑appropriate analytical development, covering identity, purity, structure (NMR, MS), impurities, elemental analysis, and bioburden/endotoxin control.

How does Abzena streamline ADC development from discovery to GMP manufacturing?

Abzena’s integrated bioconjugation and chemistry approach accelerates design, synthesis, conjugation, analytical validation, and GMP manufacturing—ensuring a de‑risked, end‑to‑end path to clinic.

Let’s move medicine forward.

The asset you’re developing right now can make a real difference for human health. Let us apply our wealth of experience to accelerate and maximize its potential.

Contact Us